On June 3, 2025, Oppenheimer analyst Matthew Hershenhorn announced the initiation of coverage on Axsome Therapeutics (AXSM, Financial). The analyst has assigned an "Outperform" rating to the stock, highlighting its potential in the market.
Oppenheimer has set a price target of $185.00 for Axsome Therapeutics (AXSM, Financial). This target reflects Oppenheimer's confidence in the company's growth prospects and strategic direction. The price target is in USD, indicating expectations for substantial gains from current levels.
Axsome Therapeutics (AXSM, Financial), traded on the NASDAQ, is under close scrutiny from investors and analysts alike, as this new coverage could signal a promising outlook. The market will be keen to see how the stock performs following the initiation.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Axsome Therapeutics Inc (AXSM, Financial) is $176.53 with a high estimate of $210.00 and a low estimate of $146.00. The average target implies an upside of 60.79% from the current price of $109.79. More detailed estimate data can be found on the Axsome Therapeutics Inc (AXSM) Forecast page.
Based on the consensus recommendation from 18 brokerage firms, Axsome Therapeutics Inc's (AXSM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Axsome Therapeutics Inc (AXSM, Financial) in one year is $259.61, suggesting a upside of 136.46% from the current price of $109.79. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Axsome Therapeutics Inc (AXSM) Summary page.
